MetGen’s biotech innovation fuels change
Finnish company MetGen has invented a revolutionary chemo-enzymatic pathway that boosts the efficiency and economics of renewable chemicals production.
MetGen’s ENZINE Technology Platform allows the design and production of the necessary enzymes for full bioconversion of glucose. No additional chemicals or co-factors are needed to perform the bioconversion. The required enzymatic solutions have not previously been commercially available.
The company has also filed a patent on the chemical route to convert the resulting sugars to oxidized forms of 5-HMF, seeking to capitalise on its efficient dehydration.
MetGen’s MetZyme enzymatic solutions cover the entire bio-based value chain from feedstock to high-value chemicals and enable the use of cellulosic feedstocks, as well as the creation of entirely new bio-based materials.
The company’s latest innovation also applies to the conversion of all types of cellulosic sugars to more easily chemically convertible sugars. This is believed to represent a major boost to the cost-competitiveness of any biorefinery concept. It therefore has potential to play a key role in accelerating the displacement of fossil fuels as a feedstock by bio-based alternatives.
This latest development follows the news from late last year that the company was awarded at the European Forum for Industrial Biotechnology and the Bioeconomy (EFIB).